Managing thrombosis in cancer patients

被引：35
作者：
Wang, Tzu-Fei [1 ]
Li, Ang [2 ]
Garcia, David [2 ]
机构：
[1] Ohio State Univ, Div Hematol, Columbus, OH 43210 USA
[2] Univ Washington, Sch Med, Div Hematol, Seattle, WA 98195 USA
来源：
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS | 2018年 / 2卷 / 03期
基金：
美国国家卫生研究院;
关键词：
anticoagulation; cancer-associated thrombosis; deep vein thrombosis; malignancy; pulmonary embolism; Venous thromboembolism; RECURRENT VENOUS THROMBOEMBOLISM; MOLECULAR-WEIGHT HEPARIN; DEEP-VEIN THROMBOSIS; ACTIVE CANCER; P-SELECTIN; INTRACRANIAL HEMORRHAGE; SECONDARY PREVENTION; PULMONARY-EMBOLISM; DOSE-ESCALATION; TISSUE FACTOR;
D O I：
10.1002/rth2.12102
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Venous thromboembolism is a major complication in cancer patients. The basis for the strong association between cancer and thrombosis remains incompletely understood, and the optimal approaches to both the treatment and the prevention of cancer-associated thrombosis are evolving. Here we review several important topics related to cancer-associated thromboembolism, including the pathogenesis, prevention, and management of this disease. Wherever possible, we include evidence from clinical trials, including the results of recently published trials that compared direct oral anticoagulants to low-molecular-weight heparin for the treatment of cancer-associated thrombosis.
引用
收藏
页码：429 / 438
页数：10
相关论文
共 72 条
  • [1] [Anonymous], 2014, COCHRANE DATABASE SY, DOI DOI 10.1002/14651858.CD008500.PUB3
  • [2] High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS)
    Ay, Cihan
    Simanek, Ralph
    Vormittag, Rainer
    Dunkler, Daniela
    Alguel, Guelay
    Koder, Silvia
    Kornek, Gabriela
    Marosi, Christine
    Wagner, Oswald
    Zielinski, Christoph
    Pabinger, Ingrid
    [J]. BLOOD, 2008, 112 (07) : 2703 - 2708
  • [3] Prediction of venous thromboembolism in cancer patients
    Ay, Cihan
    Dunkler, Daniela
    Marosi, Christine
    Chiriac, Alexandru-Laurentiu
    Vormittag, Rainer
    Simanek, Ralph
    Quehenberger, Peter
    Zielinski, Christoph
    Pabinger, Ingrid
    [J]. BLOOD, 2010, 116 (24) : 5377 - 5382
  • [4] Clinical impact of major bleeding in patients with venous thrombo-embolism treated with factor Xa inhibitors or vitamin K antagonists
    Bleker, Suzanne M.
    Brekelmans, Marjolein P. A.
    Eerenberg, Elise S.
    Cohen, Alexander T.
    Middeldorp, Saskia
    Raskob, Gary
    Buller, Harry R.
    [J]. THROMBOSIS AND HAEMOSTASIS, 2017, 117 (10) : 1944 - 1951
  • [5] Malignancies, prothrombotic mutations, and the risk of venous thrombosis
    Blom, JW
    Doggen, CJM
    Osanto, S
    Rosendaal, FR
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (06): : 715 - 722
  • [6] Efficacy and Safety of Rivaroxaban in Patients with Venous Thromboembolism and Active Malignancy: A Single-Center Registry
    Bott-Kitslaar, Dalene M.
    Saadiq, Rayya A.
    McBane, Robert D.
    Loprinzi, Charles L.
    Ashrani, Aneel A.
    Ransone, Teresa R.
    Wolfgram, Alissa A.
    Berentsen, Michelle M.
    Wysokinski, Waldemar E.
    [J]. AMERICAN JOURNAL OF MEDICINE, 2016, 129 (06) : 615 - 619
  • [7] Inferior vena cava filters in patients with cancer and venous thromboembolism (VTE): patterns of use and outcomes
    Brunson, Ann
    Ho, Gwendolyn
    White, Richard
    Wun, Ted
    [J]. THROMBOSIS RESEARCH, 2016, 140 : S132 - S141
  • [8] Clinical challenges in patients with cancer-associated thrombosis: Canadian expert consensus recommendations
    Carrier, M.
    Lazo-Langner, A.
    Shivakumar, S.
    Tagalakis, V.
    Gross, P. L.
    Blais, N.
    Butts, C. A.
    Crowther, M.
    [J]. CURRENT ONCOLOGY, 2015, 22 (01) : 49 - 59
  • [9] Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH
    Carrier, M.
    Khorana, A. A.
    Zwicker, J. I.
    Noble, S.
    Lee, A. Y. Y.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 (09) : 1760 - 1765
  • [10] Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients
    Carrier, M.
    Le Gal, G.
    Cho, R.
    Tierney, S.
    Rodger, M.
    Lee, A. Y.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 (05) : 760 - 765
12345678